Spruce Biosciences, Inc. Common Stock Cash Flow Conversion Efficiency
Spruce Biosciences, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Spruce Biosciences, Inc. Common Stock (SPRB) has a cash flow conversion efficiency ratio of -0.264x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.12 Million) by net assets ($83.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Spruce Biosciences, Inc. Common Stock (2018–2025)
Cash flow conversion efficiency of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. This chart illustrates how Spruce Biosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SPRB share price today for real-time trading data and today's change.
Spruce Biosciences, Inc. Common Stock Cash Flow Conversion Ratio Explained
Spruce Biosciences, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Spruce Biosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spruce Biosciences, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see SPRB company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Zone King Environmental Sci&Tech Co Ltd
SHG:688701
|
0.069x |
|
Fortune Information Systems Corp
TW:2468
|
0.097x |
|
Ekovest Bhd
KLSE:8877
|
0.159x |
|
Basso Industry Corp
TW:1527
|
0.014x |
|
Orion Minerals Ltd
AU:ORN
|
-0.059x |
|
Vitro S.A.B. de C.V
MX:VITROA
|
0.205x |
|
Eastern Co
NASDAQ:EML
|
0.031x |
|
Daedong Ind
KO:000490
|
0.016x |
Annual Cash Flow Conversion Efficiency for Spruce Biosciences, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. Review cash generation quality of Spruce Biosciences, Inc. Common Stock to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $42.52 Million | $-33.33 Million | -0.784x | +59.63% |
| 2024-12-31 | $28.82 Million | $-55.96 Million | -1.942x | -346.47% |
| 2023-12-31 | $76.51 Million | $-33.27 Million | -0.435x | +28.54% |
| 2022-12-31 | $68.49 Million | $-41.68 Million | -0.609x | -88.94% |
| 2021-12-31 | $111.37 Million | $-35.88 Million | -0.322x | -74.92% |
| 2020-12-31 | $149.43 Million | $-27.52 Million | -0.184x | -144.72% |
| 2019-12-31 | $-30.64 Million | $-12.62 Million | 0.412x | -14.45% |
| 2018-12-31 | $-17.80 Million | $-8.57 Million | 0.481x | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more